The Aim of the Study is to Check Whether Follicular Fluid Evaluation Using a Spectrophotometer Can Differentiate High Quality Oocytes From Low Quality Oocytes. Oocyte Quality Will be Defined Using GDF9, BMP15 and Oocyte Morphology.

Oocyte Quality Assessment Using Spectrophotometer

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07329998

Enrollment

200

Registered

2026-01-09

Start date

2024-09-22

Completion date

2026-11-01

Last updated

2026-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oocyte Quality Assessment Using Spectrophotometer

Brief summary

The aim of the study is to check whether follicular fluid evaluation using a spectrophotometer can differentiate high quality oocytes from low quality oocytes. Oocyte quality will be defined using GDF9, BMP15 and oocyte morphology. The correlation between cortisol levels in women and oocyte quality parameters will be estimated.

Interventions

PROCEDUREOocyte quality assessment using spectrophotometer

On the OPU (ovum pick-up) day the following blood biochemical markers will be measured as well- Blood interleukins 1-6, cytokine, hormone profile, lipid profile, cortisol. After collecting the oocytes- the Follicular fluid will be sent for the following tests- 1. mid-infrared spectrometry, 2. P, E2, testosterone, cortisol, cytokines, IL 1-6, lipids, fatty acids. 3. BMP-15, GDF-9 and HSPG2 4. GCMS-Gas Chromatography Mass Spectrophotometer

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Women aged 20-40 years. * Undergoing IVF or IVF-ICSI treatment. * At least five follicles visualized on ultrasound at the time of oocyte retrieval * Ability to provide written informed consent.

Exclusion criteria

* Age \>40 years. * Fewer than five follicles at the time of oocyte retrieval. * Use of donor oocytes. * Significant medical comorbidities affecting ovarian function. * Known ovarian malignancy or prior ovarian surgery significantly affecting follicular integrity.

Design outcomes

Primary

Measure	Time frame	Description
Difference in follicular fluid infrared spectrophotometric profiles between high-quality and low-quality oocytes.	3 Years	Infrared spectrophotometric measurements of follicular fluid collected at oocyte retrieval will be obtained using attenuated total reflection Fourier-transform infrared spectroscopy (ATR-FTIR). Oocytes will be classified as high-quality or low-quality based on predefined morphological criteria and follicular fluid levels of GDF9 and BMP15 measured by ELISA. The primary outcome will be reported as differences in normalized spectral absorbance features between the two oocyte quality groups, including discrimination performance using multivariate analysis.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026